The FDA today announced a proposed rule that would amend regulations concerning the use of master files for biologics. According to the FDA, this rule is necessary to avoid any disruption to products that will transition from regulation as drugs to regulation as biologics in 2020.
The FDA today announced a proposed rule that would amend regulations concerning the use of master files for biologics. According to the FDA, this rule is necessary to avoid any disruption to products that will transition from regulation as drugs to regulation as biologics in 2020.
The rule applies to products that are currently approved under the Federal Food, Drug, and Cosmetics Act but are slated to be transitioned to licensure under the Public Health Service (PHS) Act in March 2020, and it would allow these products to continue to rely, by reference, on information on a drug substance, drug substance intermediate, or drug product (DS/DSI/DP) that is contained in master files after the products make their transition.
Master files are submissions to the FDA that can be used to provide detailed, confidential information about topics including facilities, processes, or articles used in the manufacturing, processing, packaging, or storage of a product. The information contained in such a file can be used to support a submission by a drug sponsor, and the FDA generally allows Biologics License Applications to incorporate, by reference, information contained in these files.
The holder of such a file can authorize applicants or sponsors to refer to information in the file in their submissions to the FDA without having to disclose that information—such as trade secrets or confidential commercial information—to the applicants or sponsors. Incorporation by reference allows the FDA to review this information in the file in the context of a regulatory application.
The rule also codifies the FDA’s current practice, which allows a biologic product in a Biologics License Application to incorporate by reference information (other than DS/DSI/DP information) contained in a master file. This type of information may be related to excipients, stabilizers, penetrants, or other materials. However, as a scientific matter, the FDA requires applicants to submit information on DS/DSI/DP directly, without relying on a file, in part because biologics have features that can be sensitive to changes in manufacturing processes.
However, the FDA allows the use of DS/DSI/DP information in Investigational New Drug Applications, in part to help facilitate development; the new rule would also codify this practice for products subject to the PHS Act.
The FDA says that, to date, it has identified approximately 89 products that will transition, and approximately 17 of them currently incorporate by reference information on DS/DSI/DP.
The FDA will receive comments on the proposed rule for 60 days after the rule is published in the Federal Register.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.